Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Navigating Frontline Treatment With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

Jessica Hergert
Published: Tuesday, Jan 14, 2020

Denise Yardley, MD

Denise A. Yardley, MD

With the approval of 3 CDK4/6 inhibitors, the frontline treatment landscape of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer has evolved with chemotherapy no longer being the go-to approach, said Denise A. Yardley, MD. 

In March 2017, the FDA granted a full approval to palbociclib (Ibrance) in combination with letrozole as a frontline treatment for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, based on data from the confirmatory phase III PALOMA-2 trial (NCT01740427). Palbociclib is also indicated for use in combination with other aromatase inhibitors (AIs) in this setting.

In April 2019, the FDA expanded the indication for palbociclib plus an AI to include men with HR-positive, HER2-negative advanced or metastatic breast cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication